ArticleInternational journal of health policy and management2017
Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies.
Article in International journal of health policy and management, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Understanding "Alert Fatigue" in Primary Care: Qualitative Systematic Review of General Practitioners Attitudes and Experiences of Clinical Alerts, Prompts, and Reminders.Journal of medical Internet research · 2025Pooled it
- Defining the clinician's role in early health technology assessment during medical device innovation - a systematic review.BMC health services research · 2019Pooled it
- Using the NASSS-Complexity Assessment Tool to Evaluate the Implementation of "Cadê O Kauê?": Chat-Story Intervention for Youth Participation in Mental Health Promotion in Brazil.Journal of medical Internet research · 2026Article
- Exploring Acceptability, Barriers, and Facilitators for Digital Health in Dermatology: Qualitative Focus Groups With Dermatologists, Nurses, and Patients.JMIR dermatology · 2024Article
- Economic evaluations in medical technological innovations a mapping review of methodologies.Cost effectiveness and resource allocation : C/E · 2024Review
- MedTech start-ups: A comprehensive scoping review of current research trends and future directions.PloS one · 2024Article
- Photoacoustic imaging on its way toward clinical utility: a tutorial review focusing on practical application in medicine.Journal of biomedical optics · 2023Review
- The potential value of disease-modifying therapy in patients with spinocerebellar ataxia type 1: an early health economic modeling study.Journal of neurology · 2023Article
- Factors that influence the adoption of rehabilitation technologies: a multi-disciplinary qualitative exploration.Journal of neuroengineering and rehabilitation · 2023Article
- Implementing internet-delivered cognitive behavioral therapy in healthcare services: a qualitative exploration of stakeholder experience.Frontiers in digital health · 2023Article
- Using the Stay Strong App for the Well-being of Indigenous Australian Prisoners: Feasibility Study.JMIR formative research · 2022Article
- Towards early and broad evaluation of innovative surgical devices: integrating evidence synthesis, stakeholder involvement, and health economic modeling into the clinical research stages of the IDEAL framework.BMJ surgery, interventions, & health technologies · 2022Review
- Effect of medical innovation policies on the prevention and control of the COVID-19 and the impact of the "Belt and Road" economy.Frontiers in public health · 2022Article
- The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing-Remitting Multiple Sclerosis.PharmacoEconomics · 2022Article
- Article
- Initial experience with a suprapubic single-port robotic right hemicolectomy in patients with colon cancer.Techniques in coloproctology · 2021Article
- Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic.British journal of clinical pharmacology · 2021Review
- Social Non-profit Bioentrepreneurship: Current Status and Future Impact on Global Health.Frontiers in public health · 2021Review
- The NASSS framework for ex post theorisation of technology-supported change in healthcare: worked example of the TORPEDO programme.BMC medicine · 2019Article
- Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling.International journal of health policy and management · 2019Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNew technologies constitute an important cost-driver in healthcare, but the dynamics that lead to their emergence remains poorly understood from a health policy standpoint. The goal of this paper is to clarify how entrepreneurs, investors, and regulatory agencies influence the value of emerging health technologies.
methodsOur 5-year qualitative research program examined the processes through which new health technologies were envisioned, financed, developed and commercialized by entrepreneurial clinical teams operating in Quebec's (Canada) publicly funded healthcare system.
resultsEntrepreneurs have a direct influence over a new technology's value proposition, but investors actively transform this value. Investors support a technology that can find a market, no matter its intrinsic value for clinical practice or healthcare systems. Regulatory agencies reinforce the "double" value of a new technology-as a health intervention and as an economic commodity-and provide economic worth to the venture that is bringing the technology to market.
conclusionPolicy-oriented initiatives such as early health technology assessment (HTA) and coverage with evidence may provide technology developers with useful input regarding the decisions they make at an early stage. But to foster technologies that bring more value to healthcare systems, policy-makers must actively support the consideration of health policy issues in innovation policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.